Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced that Solera Health has expanded Dario's digital offerings to include a broader hypertension program, now covering pre-hypertensive members through Stage 2 hypertension.

This more than doubles Dario's addressable market within Solera's network, tying revenue to engagement, longitudinal outcomes and recurring, year-long member experiences.

Positive

• Addressable hypertension market within Solera network more than doubled
• Expanded access into large, predominantly non-diabetic hypertension population
• Revenue model tied directly to engagement and clinical improvement outcomes
• Year-long structured programs support durable results and recurring revenue
• Channel leverage through Solera's established payer and employer relationships
• Incremental upsell via client-elected modular program extensions across CMB conditions

Negative

• None.

News Market Reaction – DRIO

-4.45%

1 alert

-4.45% Session close to close

$53.38M Market Cap

1.0x Rel. Volume

In the May 26 session, DRIO declined 4.45%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands DRIO’s hypertension offering within Solera’s network, more than doubling i...

Analysis

This announcement expands DRIO’s hypertension offering within Solera’s network, more than doubling its addressable market to over 500,000 eligible lives and deepening coverage from pre‑hypertensive through Stage 2 hypertension. It reinforces a value-based model where revenue is linked to engagement and clinical outcomes. In context of recent earnings and capital-raising flexibility, investors may watch how quickly this broader reach translates into contracted lives, revenue visibility, and improved profitability metrics.

Key Figures

Eligible lives: >500,000

1 metrics

Eligible lives >500,000 Expanded hypertension program reach within Solera Health’s network

Historical Context

5 past events · Latest: May 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Q1 2026 earnings	Negative	-6.7%	Soft revenue and ongoing losses drove a -6.68% reaction.
May 04	Earnings date set	Neutral	+2.0%	Scheduling the Q1 call led to a modest 2.05% move.
Apr 20	Clinical outcomes data	Positive	+2.8%	Peer‑reviewed behavioral health results coincided with a 2.75% gain.
Apr 13	Board appointment	Positive	+1.2%	Adding an experienced director aligned with a 1.24% increase.
Mar 19	FY 2025 earnings	Negative	-7.7%	Revenue decline and losses were followed by a -7.73% move.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news events have typically seen price moves that align with the apparent tone of the announcements.

Recent Company History

Over the last few months, DRIO has balanced growth initiatives with financial pressures. Earnings on March 19 and May 13 showed revenue declines but improving cost structure, with negative price reactions of -7.73% and -6.68%. In contrast, positive strategic and clinical updates—such as the JMIR behavioral health study on April 20 and the board appointment on April 13—produced modest gains. Today’s expansion of the Solera hypertension program fits the pattern of commercially focused, positive news following earlier partnership- and outcomes-driven developments.

Key Terms

hypertension, pre-hypertensive, stage 2 hypertension, cardiometabolic, +4 more

8 terms

hypertension medical

"Hypertension represents one of the largest unmet needs in healthcare, affecting nearly half..."

Hypertension is a condition where blood pressure in the arteries remains consistently high, making the heart work harder than normal to pump blood through the body. For investors, it can signal underlying health issues that might lead to increased medical costs or decreased productivity, potentially affecting a company's stability or the overall economy. Think of it as a warning sign of ongoing strain within a system that needs careful monitoring.

pre-hypertensive medical

"by extending program reach into pre-hypertensive members through Stage 2 hypertension..."

A pre-hypertensive condition means a person’s blood pressure is higher than normal but not yet high enough to be classified as hypertension; it’s a warning stage where lifestyle changes or early treatment can prevent progression. For investors, this matters because a large or growing pool of people in this intermediate category can drive demand for preventive medicines, monitoring devices, wellness programs and diagnostic testing — similar to a dashboard warning light that signals future repair needs.

stage 2 hypertension medical

"into pre-hypertensive members through Stage 2 hypertension, Dario more than doubles..."

A medical diagnosis for consistently high blood pressure where readings are well above normal and typically indicate a need for stronger treatment or monitoring; think of it as a car’s warning light that stays on and signals a serious problem needing fixes beyond routine care. It matters to investors because prevalence and severity affect demand for drugs, devices and services, influence clinical trial markets and regulatory attention, and can change healthcare costs and insurer liabilities.

cardiometabolic medical

"deliver scalable value across cardiometabolic conditions NEW YORK, May 26, 2026 -- DarioHealth..."

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

ai-driven engagement engine technical

"Dario's core capabilities include its AI-driven engagement engine, connected devices..."

A AI-driven engagement engine is software that uses artificial intelligence to tailor, time and automate interactions with customers or users across channels like email, apps and websites. Think of it as a smart conductor that learns preferences and behavior to deliver the right message to the right person at the right moment; investors care because it can boost customer retention, increase sales and lower marketing costs, making growth more scalable and measurable.

connected devices technical

"include its AI-driven engagement engine, connected devices and personalized human coaching..."

Connected devices are everyday gadgets that can communicate and share information over the internet without human intervention, such as smart thermostats, security cameras, or wearable fitness trackers. They matter to investors because they enable new services and generate data that can create business opportunities, influence market trends, and drive growth in technology-related sectors.

value-based framework model financial

"Value-based framework model: Program structured around meaningful engagement..."

A value-based framework model is a method for judging a product, service, or investment by comparing its costs to the measurable benefits it delivers, such as better outcomes, lower long-term expenses, or improved efficiency. For investors, it matters because these models influence pricing, reimbursement, and adoption decisions—like a report card that helps buyers and payers decide if something is worth paying more for, which in turn affects a company’s revenue and risk profile.

clinical outcomes medical

"Value-based framework model: Program structured around meaningful engagement and clinical outcomes"

Clinical outcomes are the measurable results that show how well a medical treatment, device or test works for patients—examples include symptom improvement, survival rates, side effects and quality-of-life changes. Investors watch these results like a product’s report card because strong, clear outcomes can lead to regulatory approval, wider use by doctors and higher sales, while weak outcomes can limit a therapy’s market and value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expansion driven by highly successful partnership based on Dario's consistent ability to engage members and deliver scalable value across cardiometabolic conditions

NEW YORK, May 26, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that its largest network partner to date, Solera Health, a leading digital health network connecting curated solutions to employers, health plans and other payers, has broadened Dario's digital health offerings on its platform to include an expanded hypertension program. Hypertension represents one of the largest unmet needs in healthcare, affecting nearly half of all U.S. adults, and by extending program reach into pre-hypertensive members through Stage 2 hypertension, Dario more than doubles its addressable market within the Solera network.

"This expansion reflects a meaningful evolution in the economics of our Solera relationship, further reinforcing Dario's position as a select in-network partner within Solera's carefully curated digital network," said Steven Nelson, President and Chief Commercial Officer of Dario. "By going deeper across all stages of hypertension, we are accessing a materially larger population and tying revenue more directly to longitudinal outcomes, which strengthens both predictability and long-term value creation."

"Dario has consistently demonstrated the ability to engage members and translate that engagement into meaningful outcomes," said John Santelli, Chief Executive Officer of Solera Health. "As we continue to curate a high-quality, outcomes-focused network for our clients, Dario stands out for its ability to deliver scalable value across cardiometabolic conditions. Expanding the hypertension program reach strengthens our offering and helps clients address one of the most prevalent and costly health challenges facing their populations."

Dario's core capabilities include its AI-driven engagement engine, connected devices and personalized human coaching, all of which support sustained behavior change and improved cardiometabolic outcomes over time. Members are supported through a structured, year-long experience with the opportunity for continued engagement, enabling durable results and recurring revenue.

Strategic Highlights:

• Expanded access: Entry into a large, predominantly non-diabetic hypertension population
• Channel leverage: Scalable growth through Solera's established payer and employer relationships
• Modular adoption: Incremental upsell opportunities via client-elected program extensions
• Outcomes alignment: Revenue tied directly to engagement and clinical improvement
• Multiplier effect: Tackling cardiometabolic (CMB) conditions in parallel affords heightened clinical improvements and downstream cost savings
• Value-based framework model: Program structured around meaningful engagement and clinical outcomes

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.  

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected impact and expansion of the Company's relationship with Solera Health, the anticipated increase in Dario's addressable market and eligible member population, the potential for recurring and outcomes-based revenue opportunities, the expected benefits and adoption of Dario's hypertension and cardiometabolic solutions, the ability of Dario's platform to improve engagement, clinical outcomes and member retention, the potential for downstream healthcare cost savings and long-term value creation, the Company's ability to expand relationships with payers, employers and network partners, and the expected scalability and commercial growth of Dario's digital health platform. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com 
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/dario-more-than-doubles-addressable-market-in-solera-healths-network-via-expanded-hypertension-program-with-dario-now-reaching-greater-than-500-000-eligible-lives-302780817.html

SOURCE DarioHealth Corp.

FAQ

How did DarioHealth (NASDAQ: DRIO) expand its hypertension program with Solera Health in May 2026?

DarioHealth expanded its hypertension program on Solera Health’s platform to include pre-hypertensive through Stage 2 hypertension members. According to Dario, this broader coverage significantly increases program reach within Solera’s curated digital health network of employers, health plans and other payers.

By how much did DarioHealth (DRIO) increase its addressable market in Solera Health’s network?

DarioHealth more than doubled its addressable market within Solera Health’s network by extending program reach across all hypertension stages. According to Dario, the expansion targets a large, predominantly non-diabetic hypertension population, one of the most prevalent unmet healthcare needs.

What does the Solera Health partnership mean for DarioHealth’s (DRIO) revenue model?

The Solera Health partnership ties DarioHealth’s revenue more directly to engagement and longitudinal clinical outcomes. According to Dario, members follow a structured, year-long experience with opportunities for continued engagement, supporting durable results and recurring revenue aligned with value-based care frameworks.

How does DarioHealth’s expanded hypertension program support cardiometabolic outcomes for DRIO members?

The expanded program uses AI-driven engagement, connected devices and personalized human coaching to drive sustained behavior change. According to Dario, tackling multiple cardiometabolic conditions in parallel can enhance clinical improvements and generate downstream cost savings for employers, health plans and other payers.

Why is Solera Health’s network important for DarioHealth (DRIO) growth in hypertension?

Solera Health is DarioHealth’s largest network partner, offering established payer and employer relationships. According to Dario, this channel leverage enables scalable growth, incremental upsell opportunities via modular program extensions, and reinforces Dario’s role as a select in-network digital health partner.

What strategic highlights did DarioHealth (DRIO) outline for its expanded hypertension program?

DarioHealth highlighted expanded access, channel leverage, modular adoption, outcomes alignment, a multiplier effect across cardiometabolic conditions, and a value-based framework model. According to Dario, these elements combine to support scalable program growth and align economics with measurable clinical engagement outcomes.